- About Us
- Career Center
- Nano-Social Network
- Nano Consulting
- My Account
Oxonica to speak at nano tech 2005, TokyoJanuary 20, 2005
Oxonica Ltd, a leading European nanotechnology company with products already launched onto the market, announces today that its Business Director of Healthcare, David Browning, will appear as a plenary speaker at the February International Nanotechnology Exhibition & Conference in Tokyo.
- Oxonica Limited was founded in 1999 and is based in Oxford, England. Currently employing 32 professional staff, the company operates in the exciting area of nanomaterials and is application focused with a portfolio of in-house developed new product opportunities. It also commercialises IPR researched over many years in The University of Oxford
- Key enabling areas include physics, materials science, chemistry and biochemistry. Oxonica currently offers commercial products in the fields of fuel catalysis and personal care and is developing a suite of products for applied diagnostics across and beyond the healthcare space
- Oxonica's technology allows it to successfully design, manipulate and engineer certain properties of materials at the nano-scale. It has a rapidly expanding portfolio in excess of 25 patent families covering materials and applications of commercial significance
- Oxonica's intellectual property derives from a compelling combination of key technology pillars: solid state physics, colloidal chemistry, coating technology and molecular biology. A large number of potential materials with differing functionalities and surface properties can be generated by Oxonica
Lead products include:
Marketing & PR, Oxonica
Tel +44 (0) 1865 856 728
Island House, Forest Road, Guernsey, GY8 0AB UK
Tel +44 (0) 1481 233080
Fax +44 (0) 1481 233082
Copyright © Oxonica
If you have a comment, please Contact us.
Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.
A first glimpse inside a macroscopic quantum state March 28th, 2015
DFG to Establish One Clinical Research Unit and Five Research Units: New Projects to Investigate Complications in Pregnancy, Particle Physics, Nanoparticles, Implants and Transport Planning / Approximately 13 Million Euros in Funding for an Initial Three-Year Period March 28th, 2015